MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study

    S. Isaacson, A. Espay, R. Pahwa, T. Clinch, P. LeWitt (Boca Raton, FL, USA)

    Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…
  • MDS Virtual Congress 2020

    Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)

    J.R Menezes, R.B Carra, G.A Nunes, J.S Simões, M.J Teixeira, K.P Duarte, D.C Andrade, E.R Barbosa, M.A Marcolin, R.G Cury (São Paulo, Brazil)

    Objective: To study the safety and efficacy of transcutaneous magnetic spinal cord stimulation (SCS) on freezing of gait (FoG) and other motor symptoms in a…
  • MDS Virtual Congress 2020

    Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics

    M.J Peterschmitt, T. Gurevich, T. Gasser, H. Saiki, S. Isaacson, C. Waters, A.M Wills, S. Hassin-Baer, T. Simuni, N. Hattori, S. Gaemers, S.P Sardi, S. Saubadu, P. Minini, T. Fischer (Cambridge, MA, USA)

    Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…
  • MDS Virtual Congress 2020

    Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study

    S. Stodtmann, M. Rosebraugh, W. Robieson, M. Facheris (North Chicago, IL, USA)

    Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…
  • MDS Virtual Congress 2020

    Ambulosono: A Novel Sensor-based System for Quantitative Evaluation Freezing of Gait in Parkinson’s disease

    W. Xian, B. Hu, L. Chen, Z. Pei (Guangzhou, China)

    Objective: We prospectively evaluated the manifestations of On-Drug freezing of gait (FOG) of Parkinson’s disease (PD) in China using a novel sensor-based system. Background: FOG…
  • MDS Virtual Congress 2020

    Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model

    L. Bu, Y. Lu, Y. Liang, Y. Chen, S. Peng (Guangzhou, China)

    Objective: To clarity the effects and mechanism of poly-ADP-ribose polymerase 1(PARP1) in regulating mitochondrial fusion/fission in a rotenone-induced Parkinson's disease (PD) model. Background: Accumulating evidences…
  • MDS Virtual Congress 2020

    Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis

    J. Ferreira, W. Poewe, A. Antonini, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study

    P. Huang, YY. Li, P. Huang, Q. Xiao, Y. Wang, S. Chen, S.D Chen, J. Liu, Y.W Wu (Shanghai, China)

    Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Beta-adrenoreceptor medications and risk of Parkinson’s disease

    X. Li, L. Wang, Y. Zhang (Guangzhou, China)

    Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…
  • MDS Virtual Congress 2020

    Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)

    Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley